Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

About this update from Royalty Pharma Plc

[{"type":"image","alt":"Royalty Pharma plc","displaySize":"","headline":null,"caption":"Royalty Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":19,"url":"https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4OeiHB7vOJ5wAHZW8RfEkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cfd389aedb614eb79e7cc5d41fbda9e7","width":300,"height":19}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion ","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":360,"olType":false},{"type":"text","content":"NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board, will discuss these updates on January 13, 2026 as part of a webcast presentation to be held at 12:45 p.m. Eastern Time / 9:45 a.m. Pacific Time at the 44th Annual J.P. Morgan Healthcare Conference.","length":452,"tagName":"p"},{"type":"text","content":"“2025 was a landmark year for Royalty Pharma. We are on track to deliver our full-year guidance for 14%-16% top-line growth, as discussed on our third quarter 2025 earnings call, maintaining our track record of double-digit growth,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We strengthened our business through internalizing our external manager and we announced $4.7 billion in royalty transactions. This progress comes at a time when the royalty market reached $10 billion for the first time, underscoring the life sciences industry’s growing recognition of the benefits of royalty funding, including the increasing use of innovative synthetic royaltie...

More updates from Royalty Pharma Plc